AB 1785 makes manufacturers, wholesalers, retailers, and other suppliers that sell or export a long list of controlled-substance precursor chemicals report those transactions to the California Department of Justice (DOJ). The bill also requires pre-sale verification (a letter of authorization plus multiple forms of identification), establishes timing rules for reports and export notifications, and creates criminal and financial penalties for noncompliance.
The measure clarifies that online retailers and online fulfillment methods fall within the statute’s definition of “retail distributor,” and it centralizes state-level oversight by preempting local ordinances. For supply-chain participants, compliance will mean new intake procedures, recordkeeping practices, and potential reporting workflows tied to both domestic and foreign customers.
At a Glance
What It Does
The bill requires suppliers to submit transaction reports to the California DOJ for a defined list of precursor substances and gives DOJ authority to add or remove substances by regulation (with a March 1-year-after adoption expiration on any change). Sellers must collect a letter of authorization containing a business license or DEA registration and keep purchaser identification records for three years. Reports generally must be filed at least 21 days before delivery, though the DOJ can allow monthly reporting for regular, established supply relationships; exporters must notify DOJ on or before exportation with an option for monthly notices when a pattern is established.
Who It Affects
Manufacturers, wholesalers, retailers (including online retailers that fulfill orders by delivery, in-person pickup, or curbside), freight carriers maintaining manifests, and entities that import or export precursor chemicals. Pharmacies, licensed health facilities, DEA-registered analytical labs, and other exempted medical or licensed actors remain in-scope for specific recordkeeping or exception rules.
Why It Matters
This bill creates a single statewide reporting and verification regime for precursor sales that will change intake and fulfillment operations across supply chains, particularly for online channels. It also sharpens DOJ’s ability to update the regulated list quickly and imposes criminal and substantial financial penalties that raise compliance risk for suppliers and logistics partners.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
AB 1785 targets a long roster of precursor chemicals and reagents commonly used to make illicit controlled substances. The bill lists specific chemicals (from phenylacetic acid, ephedrine and pseudoephedrine, to gamma-butyrolactone, red phosphorus, iodine, and others) and allows the Department of Justice to modify that list by regulation.
Importantly, any addition or deletion the DOJ makes by regulation expires on March 1 of the year following the calendar year during which the regulation was adopted, which forces periodic review or re-adoption to keep changes in force.
Before completing a transaction, the seller must obtain and retain a letter of authorization that names the purchaser, shows a current business license number or DEA registration if available, gives the business address, and describes lawful use. Sellers also must get “proper identification” from purchasers — a combination of identifiers such as federal tax ID, seller’s permit, city business license, state-issued ID, DEA registration, or a DOJ precursor business permit.
The bill explicitly protects trade-secret process details by permitting a description of intended legitimate use without forcing disclosure of proprietary chemical processes.For cross-border shipments, exporters must notify DOJ on or before exportation with substance name, quantity, and recipient information; DOJ can permit monthly notifications for regular export relationships. For domestic deliveries, suppliers generally must report transactions at least 21 days before delivery to DOJ, though the department can authorize monthly reporting for repetitive, regular supply patterns where lawful use has been established.
The seller must sign as a witness to purchaser identification and must keep carrier manifests for three years when a common carrier is used.The statute also builds in a set of exemptions and consumer-sale limitations. Licensed practitioners, prescriptions, licensed pharmacies supplied by licensed manufacturers/wholesalers, DEA-registered analytical research labs, and state-licensed health care facilities are carved out in defined ways.
Over-the-counter products containing ephedrine family compounds remain exempt except when an individual transaction exceeds three packages or nine grams (with an explicit pediatric-liquid carveout). The bill bans sales to, and possession by, persons under age 18 of the listed substances (subject to the OTC exemptions).
Finally, the Act forbids local governments from imposing their own sale rules for the specified OTC products, making California’s rules the uniform standard statewide.
The Five Things You Need to Know
Sellers must report qualifying precursor transactions to the California DOJ at least 21 days before delivery, unless DOJ authorizes monthly batch reporting for established, lawful supply chains.
A letter of authorization must include the purchaser’s current business license number or DEA registration, business address, and a nonproprietary description of intended lawful use; sellers must retain this and purchaser ID records for three years.
The bill makes first reporting violations punishable by up to six months in county jail and a fine up to $5,000; repeat violations carry exposure up to one year in county jail or state imprisonment and fines up to $100,000.
For over-the-counter ephedrine/pseudoephedrine products, the statute prohibits any single transaction sale of more than three packages or more than nine grams (pediatric liquid forms are carved out by dosage and container-size limits).
The definition of “retail distributor” expressly covers online retailers and online sales fulfilled by delivery, in-person pickup, or curbside pickup, and the bill preempts local ordinances governing such OTC sales.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Substances covered and DOJ rulemaking authority
This subsection lists the specific chemicals and materials subject to reporting — a mix of organic precursors (e.g., phenylacetic acid), amines (e.g., methylamine), ephedrine-family stimulants, solvents and reagents (e.g., thionyl chloride, gamma-butyrolactone), and reactive elements (e.g., red phosphorus, iodine). It also permits the DOJ to add or delete items by regulation; any regulatory change expires on March 1 of the year following the calendar year when adopted, forcing renewal or legislative action to make permanent changes.
Temporary regulatory additions and expirations
This subsection authorizes standard regulatory rulemaking under the Government Code and includes the unusual sunset-like constraint: any added or deleted substance has no effect beyond March 1 of the year after adoption. Practically, DOJ can act quickly to respond to emerging precursor threats but must re-adopt or otherwise renew changes promptly to maintain continuity.
Pre-sale verification, letter of authorization, and identification
Sellers must obtain a letter of authorization from purchasers that lists a current business license or DEA registration, the business address, and a description of lawful use; sellers must also collect proper identification (a combination of identifiers is required). The statute protects trade-secret process details by permitting a nonproprietary description of use. Records of authorization and ID must be readily available for three years.
Timing of reports and carrier manifest requirement
Most domestic transactions must be reported to DOJ not less than 21 days before delivery. DOJ may allow monthly reporting for recurring, lawful supplier-recipient relationships. The seller must sign as a witness to purchaser ID and, when a common carrier is used, maintain a delivery manifest for three years — a recordkeeping requirement that ties logistics providers into compliance chains.
Exemptions, OTC thresholds, under‑18 prohibition, and penalties
This cluster of provisions defines targeted exemptions: licensed practitioners acting on prescription, licensed pharmacies receiving from licensed manufacturers/wholesalers (with suspicious-sale reporting duties), DEA-registered analytical labs, and state-licensed health facilities. The statute preserves an OTC retail exemption but caps single transactions at three packages or nine grams for ephedrine-family products (with pediatric liquid exceptions). It makes sales to minors and possession by under-18s unlawful and sets misdemeanor/felony penalties for violations with escalating fines and custody exposure for repeat offenses.
Definitions and preemption of local sale rules
The bill defines terms used elsewhere — retail categories in SIC code terms, a detailed pediatric-liquid definition, and a broad definition of “retail distributor” that expressly includes online retailers and online fulfillment methods. The Legislature states an intent to preempt local ordinances on OTC sales of the specified ephedrine-family products, making this the statewide standard for those transactions.
This bill is one of many.
Codify tracks hundreds of bills on Criminal Justice across all five countries.
Explore Criminal Justice in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- State law enforcement (California DOJ) — gains centralized visibility into precursor flows and new regulatory levers to track and respond to diversion patterns, plus clearer legal authority to require information.
- Licensed pharmacies and healthcare providers — enjoy clearer exemptions and a predictable statewide standard that reduces patchwork local rules and potential enforcement surprises.
- Compliance and verification service vendors — increased demand for third-party solutions to manage letters of authorization, ID verification, and DOJ reporting workflows for manufacturers, wholesalers, and online sellers.
Who Bears the Cost
- Manufacturers, wholesalers, and retailers (including online sellers) — must build intake controls, documentation systems, and reporting workflows; small suppliers may face disproportionate compliance burdens.
- Logistics and common carriers — required to maintain manifests and could be pulled into compliance and evidentiary duties, increasing administrative work and storage obligations for three years.
- DOJ and implementing agencies — carry the operational cost of regulating, reviewing, and responding to reports, plus the administrative burden of making and re-adopting regulatory changes under the March 1 expiration rule.
Key Issues
The Core Tension
The central dilemma is speed versus stability: the bill gives DOJ the ability to react quickly to new precursor threats through regulatory additions, but the built-in expiration and the 21-day reporting rule impose recurring administrative work and business disruption — a design that helps prevent permanent overbreadth while increasing uncertainty and compliance risk for lawful suppliers.
The bill balances rapid response to emerging precursor threats against administrative complexity. Allowing DOJ to add or remove substances by regulation gives the state speed, but the rule that any change expires on March 1 of the following year creates recurring work: DOJ must decide whether to re-adopt, which can generate regulatory churn and uncertainty for suppliers who rely on stable classifications.
That expiration mechanism reduces the risk of permanent overreach but raises compliance costs because regulated parties cannot safely assume a regulatory change is permanent.
Operationally, the 21-day prior-notice requirement is a blunt tool: it is designed to give prosecutors and investigators lead time but will be awkward for just-in-time supply models, especially in online commerce and for small businesses selling legitimate products. The monthly-reporting accommodation for established lawful relationships mitigates this but shifts the burden to DOJ to identify which relationships qualify, creating discretionary gatekeeping and record-review work.
The criminal penalties are significant and include both jail and large fines; this combination raises the stakes for inadvertent reporting errors or recordkeeping lapses, particularly for businesses without robust compliance programs.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.